This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Philippe Moulin
Faculté Lyon Est, Lyon, France

Philippe Moulin is head of department of endocrinology since 2003 and professor of human nutrition since 1995 at Faculté Lyon Est, Claude Bernard Lyon 1 University France.


He is in charge of an INSERM team in the INSERM research Unit CARMEN U1060, a position he has held for the last 15 years. He is past president of the French Society of Atherosclerosis (NSFA) 2015-2017, and he organized the EAS Congress in Lyon, in 2013.


Following a post doc in Alan Tall Laboratory 1989-1991 devoted to CETP, he moved into the field of the regulation of triglyceride metabolism contributing to the identification of the first mutations of Apo AV, of auto antibodies against LPL and GPIHBP1. He proposed, thanks to a European collaboration, a phenotypic score to help in the diagnosis of Familial vs Multifactorial Chylomicronemia Syndrome.


He contributed to set up the French familial hypercholesterolemia network leading to the discovery of PCSK9. His team currently conduct research in the field of hypolipidemias. In addition to his work in dyslipidemias, he also carried out cardiovascular complications assessments as well as new vascular imaging methods in type 2 diabetes.